公开(公告)号：EP0851876A1

公开(公告)日：1998-07-08

申请号：EP96929619.0

申请日：1996-08-23

申请人： Rural Patent Svenska AB

发明人： LÖNNROTH, Ivar ,  LANGE, Stefan ,  JOHANSSON, Eva ,  JENNISCHE, Eva ,  LÖNNROTH, Christina

IPC分类号： C12N15 ,  A23K1 ,  A61K31 ,  A61K38 ,  A61P1 ,  A61P3 ,  A61P29 ,  C07K14 ,  C07K16 ,  C12N5 ,  C12P21 ,  C12Q1 ,  C12R1

CPC分类号： C07K14/47 ,  A23K20/147 ,  A61K38/00 ,  C07K14/575 ,  Y02A50/471

摘要： A new recombinant protein called Antisecretory Factor (rAF) and homologues and peptide fragments thereof are described. The protein and the homologues and fragments thereof are useful for normalizing pathological fluid transport and/or inflammatory reactions in animals including humans. Antibodics against AF or homologues or fragments thereof are described. Nucleic acids coding for the protein or for homologues or fragments thereof are also described as well as vectors and hosts comprising the nucleic acids. The rAF and homologues and fragments thereof could be used for immunodetection, as feed additive for growing animals and as antidiarrheal and drugs against diseases involving edema, dehydration and/or inflammation.

公开(公告)号：EP0805687A1

公开(公告)日：1997-11-12

申请号：EP96905219.0

申请日：1996-01-24

申请人： MURGITA, Robert, A.

发明人： MURGITA, Robert, A.

IPC分类号： G01N33 ,  A61K31 ,  A61K38 ,  A61K47 ,  A61K49 ,  A61K51 ,  A61P3 ,  A61P25 ,  A61P35 ,  A61P37 ,  A61P43 ,  C07K14 ,  C07K19 ,  C12N5 ,  C12N15 ,  C12P21 ,  C12R1

CPC分类号： C07K14/4715 ,  A61K38/1709 ,  A61K47/62 ,  C07K2319/00 ,  C12N2799/026 ,  Y02A50/471 ,  A61K2300/00

摘要： In general, disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof; methods of inhibiting a neoplasm in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an anti-neoplasm fragment or analog thereof; and methods of cell culture, involving the use of a media containing recombinant human alpha-fetoprotein or a fragment or analog thereof.

公开(公告)号：EP0457888B1

公开(公告)日：1996-07-10

申请号：EP91901181.7

申请日：1990-12-04

申请人： The Administrators of The Tulane Educational Fund

发明人： COY, David, H. ,  MURPHY, William, A.

IPC分类号： C07K14/655 ,  A61K38/16

CPC分类号： C07K14/6555 ,  A61K38/00 ,  Y02A50/471 ,  Y10S930/16 ,  Y10S930/26

摘要： A compound of the formula: wherein each A1 and A2, independently, is H, C1-12 alkyl, C7-10 phenylalkyl, R1CO (where R1 is C1-20 alkyl, C3-20 alkenyl, C3-20 alkinyl, phenyl, naphthyl, or C7-10 phenylalkyl), or R2OCO (where R2 is C1-10 alkyl or C7-10 phenylalkyl), provided that when one of A1 or A2 is R1CO or R2OCO, the other must be H; each X1 and X2, independently, is H, F, Cl, Br, OH, CH3, or CF3, provided that at least one of X1 and X2 must be H; A3 is Phe or Tyr; and A4 is OH, NH2, or NH-R3 (wherein R3 is a saturated aliphatic C1-8 alkyl); or a pharmaceutically acceptable salt thereof. A therapeutic composition containing the compound of the present invention and a method of using the same are also described.

公开(公告)号：EP0642351A1

公开(公告)日：1995-03-15

申请号：EP93910549.0

申请日：1993-05-21

申请人： PHAIRSON MEDICAL AB

发明人： LINDBLOM, Ragnvald ,  DE FAIRE, Johan

IPC分类号： A61K ,  A61K8 ,  A61K6 ,  A61K35 ,  A61K38 ,  A61P1 ,  A61P11 ,  A61P13 ,  A61P15 ,  A61P17 ,  A61P25 ,  A61P27 ,  A61P29 ,  A61P31 ,  A61P33 ,  A61P35 ,  A61P37 ,  A61P43 ,  A61Q5 ,  A61Q7 ,  A61Q11 ,  C12N9

CPC分类号： A61K8/66 ,  A61K8/987 ,  A61K38/00 ,  A61Q11/00 ,  C12N9/48 ,  C12N9/6402 ,  Y02A50/411 ,  Y02A50/471 ,  Y02A50/483

摘要： Non-immunogenic enzyme composition which has been isolated from antartic krill and exhibits both endo- and exo-peptidase activity, comprises essentially a single proteolytic enzyme having a molecular weight from 26,000 to 32,000, as determined by SDS-PAGE. The composition is useful in the manufacture of compositions for the treatment of dental plaque.

公开(公告)号：EP0617958A1

公开(公告)日：1994-10-05

申请号：EP92915651.1

申请日：1992-07-06

申请人： KOMISSAROVA, Irina Alexeevna ,  GUDKOVA, Julia Vasilievna ,  SOLDATENKOVA, Tatyana Dmitrievna ,  BURBENSKAYA, Natalya Mokhailovna ,  KONDRASHOVA, Tatyana Tikhonovna ,  KALANTAR, Irina Lvovna ,  TOPOROV, Jury Markelovich ,  SEMENOVA, Galina Fedorovna ,  NARTSISSOV, Rjurik Platonovich ,  KALININA, Elena Valentinovna

发明人： KOMISSAROVA, Irina Alexeevna ,  GUDKOVA, Julia Vasilievna ,  SOLDATENKOVA, Tatyana Dmitrievna ,  BURBENSKAYA, Natalya Mokhailovna ,  KONDRASHOVA, Tatyana Tikhonovna ,  KALANTAR, Irina Lvovna ,  TOPOROV, Jury Markelovich ,  SEMENOVA, Galina Fedorovna ,  NARTSISSOV, Rjurik Platonovich ,  KALININA, Elena Valentinovna

IPC分类号： A61K31/19

CPC分类号： A61K31/19 ,  Y02A50/471 ,  Y10S514/81 ,  Y10S514/811 ,  A61K2300/00

摘要： Eine pharmazeutische Komposition mit einer alkoholischen, strahlungsschützenden, anticholerischen, den Energiestoffwechsel, die säurebildende und Sekretionsfunktion der Magenschleimhaut stimulierenden Wirkung enthält als Wirkstoff eine Mischung von Bernstein- und Zitronensäure oder deren pharmazeutisch verträglichen Salzen.
Ein Verfahren zur Prophylaxe und Heilung eines alkoholischen Betrunkenheitszustandes und eines alkoholischen Abstinenzsyndroms, zur Stimulierung des Energiestoffwechsels, zur Stimulierung und Diagnostik der säurebildenden und Sekretionsfunktion der Magenschleimhaut, zum Schutz vor Strahlungsbeschädigungen und zur Prophilaxe von Cholera besteht in peroraler Einführung einer effektiven Menge der anzumeldenden pharmazeutischen Komposition.

摘要翻译： 与醇，防辐射，anticholeric动作刺激能量代谢和胃粘膜的形成酸的和分泌功能的药物组合物含有作为活性成分的琥珀酸和柠檬酸的酸或它们的药学上合适的盐的混合物。 一种用于酒精醉状态的预防和固化和醇戒断综合征的方法，用于从辐射损伤和用于刺激能量代谢，对胃粘膜的酸形成和分泌功能的刺激和诊断，用于保护 霍乱的预防包括口服引入而施用的用于将有效量的药物组合物。

公开(公告)号：EP0472434A3

公开(公告)日：1993-06-09

申请号：EP91307750.9

申请日：1991-08-22

申请人： BAYLOR COLLEGE OF MEDICINE ,  ABBOTT LABORATORIES

发明人： Lupski, James R. ,  Katz, Leonard

IPC分类号： C12N15/11 ,  A61K31/70 ,  C07H21/00 ,  C12Q1/68

CPC分类号： C12Q1/18 ,  A61K38/00 ,  C07K14/195 ,  C07K14/285 ,  C12N15/113 ,  C12N2310/3517 ,  Y02A50/471 ,  Y02A50/481

摘要： A method of treating bacterial infections comprising the step of interrupting the expression of a macromolecular synthesis operon in bacteria by hybridizing an antisense oligonucleotide to a single stranded DNA or to a mRNA transcribed from the macromolecular synthesis operon. The antisense oligonucleotide can be either sequence specific to a unique intergenic sequence or a sequence specific to a bacterial homologous sequence. By interrupting the expression of the macromolecular synthesis operon bacterial infections can be treated. Specific antisense oligonucleotides and macromolecular synthesis operon sequences are disclosed. The ability of the antisense oligonucleotide to bind the mRNA or single stranded DNA also allows the identification of the bacteria by using a unique intergenic antisense oligonucleotide to bind to the single stranded DNA or to the mRNA transcribed from the macromolecular synthesis operon. A method for competitively inhibiting the protein products of the MMS operon with oligonucleotides is also disclosed. Methods of identifying unique intergenic sequence is also disclosed.

公开(公告)号：EP0285343A3

公开(公告)日：1990-11-22

申请号：EP88302690.8

申请日：1988-03-25

申请人： UNIVERSITY COLLEGE LONDON

发明人： Shiells, Richard Anthony ,  Falk, Gertrude

IPC分类号： A61K31/455 ,  A61K31/195 ,  A61K31/52

CPC分类号： A61K31/455 ,  A61K31/52 ,  Y02A50/471 ,  Y02A50/473 ,  Y10S514/823 ,  Y10S514/922 ,  A61K31/195 ,  A61K2300/00

摘要： Nicotinamide and its analogues (but not nicotinic acid) are effective in preventing or reversing the effects of microbial toxins, e.g. pertussis toxin, which ADP-ribosylate G-proteins.

公开(公告)号：EP2300034B1

公开(公告)日：2018-08-08

申请号：EP09759182.0

申请日：2009-06-01

申请人： Dana-Farber Cancer Institute, Inc.

发明人： MUNSHI, Nikhil, C. ,  BAE, Jooeun ,  ANDERSON, Kenneth, C

IPC分类号： A61K38/00

CPC分类号： A61K39/0011 ,  A61K38/00 ,  A61K2039/55516 ,  A61K2039/55566 ,  C07K14/4702 ,  C07K14/70507 ,  Y02A50/471 ,  Y02A50/473

摘要： A pharmaceutical composition can be used for treating or preventing cancer; the composition comprising a pharmaceutically acceptable carrier and a peptide, a nucleic acid encoding said peptide, a vector comprising said nucleic acid, or a cell comprising said nucleic acid, peptide or vector; wherein said peptide consists of an amino acid sequence that is at least 66% identical to any one of SEQ ID NOS: 15-18.

公开(公告)号：EP3256139A4

公开(公告)日：2018-07-18

申请号：EP16750009

申请日：2016-02-12

申请人： UNIV PENNSYLVANIA

发明人： KOO HYUN ,  GAO LIZENG ,  CORMODE DAVID ,  NAHA PRATAP

IPC分类号： A61K9/51 ,  A01N59/16 ,  A01P1/00 ,  A61K33/26

CPC分类号： A61K8/19 ,  A01N59/16 ,  A61K8/0245 ,  A61K8/20 ,  A61K8/22 ,  A61K8/66 ,  A61K8/73 ,  A61K9/006 ,  A61K9/0063 ,  A61K9/14 ,  A61K9/5161 ,  A61K33/26 ,  A61K33/40 ,  A61K47/6923 ,  A61K2800/413 ,  A61K2800/624 ,  A61K2800/92 ,  A61Q11/00 ,  Y02A50/471 ,  Y02A50/473 ,  A61K2300/00 ,  A01N25/12 ,  A01N25/26 ,  A01N59/00 ,  A01N59/06 ,  A01N59/10 ,  A01N59/20 ,  A01N59/26

摘要： The presently disclosed subject matter relates to iron oxide nanoparticle compositions and formulations thereof for: (1) the treatment and elimination of biofilms; (2) the prevention of biofilm formation; (3) biofilm extracellular matrix degradation; (4) the inhibition of bacterial viability and growth within the biofilm; and (5) the prevention of tooth or apatitic demineralization. In particular, the presently disclosed subject matter provides a composition for the prevention and treatment of an oral disease (e.g., dental caries) that includes one or more iron oxide nanoparticles and hydrogen peroxide.

公开(公告)号：EP3339321A1

公开(公告)日：2018-06-27

申请号：EP18154875.1

申请日：2009-08-28

申请人： Taiga Biotechnologies, Inc.

发明人： REFAELI, Yosef ,  TURNER, Brian Curtis

IPC分类号： C07K14/82 ,  C07K19/00 ,  A61K38/16

CPC分类号： A61K39/39 ,  A61K38/00 ,  C07K14/001 ,  C07K14/47 ,  C07K14/82 ,  C07K2319/02 ,  C07K2319/21 ,  Y02A50/387 ,  Y02A50/406 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/471

摘要： Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.